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Molecular Diagnosis of SARS  
Enders K. O. Ng and Y. M. Dennis Lo 
 
Abstract 
The etiologic agent of severe acute respiratory syndrome (SARS) has been 
identified as a new type of coronavirus, known as SARS coronavirus (SARS-CoV). 
Although the severe acute respiratory syndrome (SARS) epidemic was subsided, 
many authorities including the World Health Organization (WHO) and the Centers for 
Disease Control and Prevention (CDC) have warned on the possible re-emergence of 
this highly infectious disease. Although antibody-based diagnosis of SARS has been 
demonstrated to be a reliable proof of SARS infection, it is not sensitive enough for 
detection during the early phase of the disease. To date based on the publicly released 
full genomic sequences of SARS-CoV, various molecular detection methods based on 
reverse transcriptase polymerase chain reaction (RT-PCR) have been developed. 
Although most of the assays have been initially focused on RNA extracted from 
nasopharyngeal aspirates, urine and stools, subsequently developed 
plasma/serum-based assays allow the precise and standardized quantitative expression 
of viral loads demonstrated to be potentially used for early SARS diagnosis. In this 
chapter, two real-time quantitative RT-PCR systems based on our recent development 
of the quantifications of SARS-CoV RNA in serum are discussed. The two RT-PCR 
systems, one towards the nucleocapsid region and the other towards the polymerase 
region of the virus genome have detection rate of 80% during the first week of illness. 
These quantitative systems not only be potentially used in early diagnosis of SARS 
but also provide the viral load information allowing clinicians to make a prognostic 
evaluation of the infected individual.  
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1. Introduction  
The recent identification of SARS-coronavirus (SARS-CoV) as the etiologic agent of 
severe acute respiratory syndrome (SARS) has led scientists to develop rapid and 
sensitive diagnostic tests (1-6). However, the progress in the development of sensitive 
and early diagnostic tests for SARS has been slower than originally expected. 
Although the severe acute respiratory syndrome (SARS) epidemic was subsided, 
many authorities including the World Health Organization (WHO) and the Centers for 
Disease Control and Prevention (CDC) have warned on the possible re-emergence of 
this highly infectious disease. Thus, the development of better diagnostic tests for 
SARS is urgently needed. Most of the diagnostic tests are not sensitive enough for 
detection during the early phase of the disease. For instance, the use of 
nasopharyngeal aspirates has a sensitivity of only 32% on day 3 of the disease (7). 
This severe limitation has restricted our ability to identify patients in a prompt manner 
and to institute isolation and treatment. 
Based on the publicly released full genomic sequences of SARS-CoV (8-10), 
various molecular detection methods based on reverse transcriptase polymerase chain 
reaction (RT-PCR) have been developed. These PCR-based diagnostic tests are used 
to detect SARS-CoV RNA in patients’ specimens in which viral RNA is 
reverse-transcribed into DNA and then different regions of the SARS-CoV genome 
are specifically amplified by PCR. Several RT-PCR protocols developed by members 
of the WHO laboratory network are available on the WHO website 
(http://www.who.int/csr/sars/primers/en/).  
RT-PCR is mainly divided into qualitative (conventional) and quantitative 
approaches. Conventional RT-PCR approaches are normally qualitative in nature and 
require time-consuming and contamination-prone post-PCR analysis. Real-time 
quantitative RT-PCR has overcome many of these shortcoming and has been 
increasingly adopted by various laboratories for SARS diagnosis (2,11-15). With 
suitable instrumentation, this technology allows data to be recorded and analyzed 
during PCR cycling. Furthermore, it runs as a closed-tube system and 
post-amplification manipulation can be eliminated. Thus, this methodology reduces 
the risk of contamination and minimizes hands-on time. The entire amplification 
process requires only 3 hours and allows such technology to be used for 
high-throughput application.  
After SARS outbreak, the PCR-based testing for SARS has mainly been focused 
on the analysis of nasopharyngeal aspirates, urine and stools (7,11). An early study 
has reported that SARS-CoV RNA was detected in 32% of nasopharyngeal aspirates 
from SARS patients studied at a mean of 3.2 days after the onset of illness and the 
detection rate increased to 68% at day 14 (7). In the same study, SARS-CoV RNA 
was detected in 97% of stool samples collected at a mean of 14.2 days after symptom 
onset. Similarly, viral RNA was detected in 42% of urine samples collected from the 
SARS patients at a mean of 15.2 days after onset (7). Despite the high sensitivity of 
stool sample testing, early detection of SARS-CoV still suffers from a lack of high 
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sensitivity. Although most of the assays have been predominantly focused on RNA 
extracted from nasopharyngeal aspirates, urine and stools, the quantitative 
interpretation of these data is difficult due to the inability to standardize such data as a 
result of the influence of numerous factors, such as sampling technique for 
nasopharyngeal aspirates, urine volume, variations of bowel transit time (e.g. during 
diarrhoea) or stool consistency. On the other hand, plasma/serum-based assays may 
allow the precise and standardized quantitative expression of viral loads, thus, 
enabling the assessment of disease severity and prognosis. Detection of viral nucleic 
acids in plasma/serum has been well-established for viral load studies for numerous 
other viruses (16,17). At the beginning of the SARS outbreak, there has been a single 
report showing the relatively low sensitivity of detecting SARS-CoV RNA in plasma 
using an ultracentrifugation-based approach, with low concentrations of SARS-CoV 
detected in the plasma of a patient 9 days after disease onset (2). Subsequently, 
together with the improvement of viral RNA extraction in which plasma or serum 
required no ultracentrifugation, two real-time quantitative RT-PCR assays, one 
towards the polymerase region and the other towards the nucleocapsid region of the 
virus genome (see Figure 1), were developed for measuring the concentration of 
SARS-CoV RNA in serum/plasma samples from SARS patients (13,14). In these 
assays, the absolute calibration curves are constructed by serial dilutions of high 
performance liquid chromatography (HPLC)-purified single stranded synthetic DNA 
oligonucleotides specifying the studied amplicons (see Figure 2). Previous studies 
have shown that such single stranded oligonucleotides reliably mimic the products of 
the reverse transcription step and produce calibration curves that are identical to those 
obtained using T7-transcribed RNA (18,19). The use of such calibration methodology 
significantly simplifies the process of obtaining a calibration curve when compared 
with the labour-intensive preparation of calibration curve involves amplicon 
subcloning and in vitro transcription.  
 The sensitivities of the amplification steps of these assays are sufficient to 
detect 5 copies of the targets in the reaction mixtures, corresponding to 74 copies/mL 
of serum (13). Using these RT-PCR assays SARS-CoV RNA was detected in 75% to 
78% of serum samples from SARS patients during the first week of illness (13). In 
the same study, data showed that median concentrations of serum SARS-CoV RNA in 
patients who required ICU admission during the course of hospitalisation was 
significantly higher than those who did not require intensive care (13) (see Figure 3). 
This quantitative test thus provides the viral load information allowing clinicians to 
make a prognostic evaluation of the infected individual. 
Recent reports revealed that the clinical course of paediatric SARS patients was 
less severe in comparison with adult SARS patients (20,21). On the whole, the 
outcomes of paediatric SARS patients were favorable. With the use of the 
plasma/serum-based quantitative RT-PCR assay, SARS-CoV RNA has recently been 
shown to be detectable in the plasma samples of paediatric patients during different 
stages of SARS (see Figure 4) (14). No significant difference in plasma SARS-CoV 
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viral load has been observed between paediatric and adult SARS patients taken within 
the first week of admission and at day 7 after fever onset (14). Overall, viraemia 
appears to be a consistent feature in both paediatric and adult SARS patients. 
The relatively high detection rate of SARS-CoV in plasma and serum during the 
first week of illness suggests that plasma/serum-based RT-PCR should be 
incorporated into the routine diagnostic workup of suspected or confirmed SARS 
patients both in adult and paediatric populations. This approach opens up numerous 
interesting research opportunities. For example, this assay can be used to monitor the 
effect or lack of effects of anti-viral agents. Also, it would be valuable to explore the 
potential damaging effect of giving steroids at a time when the viral load is still 
relatively high. We are aware that many of these questions might not be answerable 
with retrospectively collected samples. Nonetheless, the development of animal 
models (5,6) might allow the testing of some of these hypotheses in a controlled 
manner. 
In this chapter, the two systems discussed below are based on our recent 
development of the quantifications of SARS-CoV RNA in serum. The SARSN 
RT-PCR system towards the nucleocapsid region and SARSpol1 towards the 
polymerase region of the virus genome aim to measure the concentration of 
SARS-CoV RNA and demonstrated to have detection rate of 80% during the first 
week of illness. These SARS-CoV RT-PCR systems not only are used in early 
diagnosis of SARS but also provide the viral load information allowing clinicians to 
make a prognostic evaluation of the infected individual. 
 5 
2. Materials 
2.1. Sample Collection 
1. Plain collection tubes for serum collection. 
2. RNase Away (Invitrogen, Carlsbad, California). 
 
2.2. RNA Extraction 
1. QIAamp viral RNA Mini Kit (Qiagen, Hilden, Germany). 
2. Absolute ethanol 
 
2.3. Real-Time Quantitative RT-PCR 
2.3.1. Amplification Reagents 
1. Primers (see Note 1): 
a. SARSpol1: 
i. Forward: 5’-GAGTGTGCGCAAGTATTAAGTGA-3’. 
ii. Reverse: 5’-TGATGTTCCACCTGGTTTAACA-3’. 
b. SARSN: 
i. Forward: 5’-TGCCCTCGCGCTATTG-3’. 
ii. Reverse: 5’-GGCCTTTACCAGAAACTTTGC-3’. 
2. Dual-labelled Fluorescent probes (see Note 1): 
a. SARSpol1:  
5’-(FAM)ATGGTCATGTGTGGCGGCTCACTA(TAMRA)-3’. 
b. SARSN:  
5’-(FAM)TGCTAGACAGATTGAACCAGCTTG(TAMRA)-3’. 
where FAM is 6-carboxy-fluorescein; TRMRA is 
6-carboxy-tetramethylrhodamine. 
The amplicon locations of the SARSN and SARSpol1 RT-PCR systems 
are showed in Figure 1. 
 
3. Calibrators 
a. Synthetic DNA oligonucleotides specifying the polymerase gene of 
SARS-CoV genome, HPLC purified (Proligos, Singapore) (see Note 
2): 
5’-AACGAGTGTGCGCAAGTATTAAGTGAGATGGTCATGTGT
GGCGGCTCACTATATGTTAAACCAGGTGGAACATCATCCGG 
-3’. 
b. Synthetic DNA oligonucleotides specifying the nucleocapsid gene of 
SARS-CoV genome, HPLC purified (Proligos, Singapore) (see Note 
2): 
5’-GAAACTGCCCTCGCGCTATTGCTGCTAGACAGATTGAAC
CAGCTTGAGAGCAAAGTTTCTGGTAAAGGCCAACAA- 3’ 
4. RNase-free water. 
5. EZ rTth RNA PCR reagent set (Applied Biosystems, Foster City, CA). 
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2.3.2. Instrumentation for Quantitative Analysis 
1. ABI Prism 7700 Sequence Detector (Applied Biosystems, Foster City, CA). 
 
3. Methods 
3.1. Prevention of contamination 
Due to the high sensitivity of RT-PCR-based approaches, strict precautions should 
be applied to prevent the RT-PCR assay from contamination (22). These precautions 
include: 
1. Aerosol-resistant pipette tips should be used for all liquid handling.  
2. Separate areas should be used for the RNA extraction step, the setting up of 
amplification reactions, the addition of template and the carrying out of 
amplification reactions.  
3. Real-time PCR approaches obviate the need for post-PCR processing and further 
reduce the risk of contamination. 
4. The assay should include a further level of anticontamination measure in the 
form of pre-amplification treatment using uracil N-glycosylase which destroys 
uracil containing PCR products (23).  
5. Multiple negative water blanks should be included in every analysis so as to 
eliminate the possibility of reagent contamination. 
 
3.2. Sample Collection 
1. Collect blood samples in plain tubes. 
To ensure a sufficient amount of serum for RNA analysis, at least 3 mL of 
blood should be taken for each sample (see Note 3). The blood samples should 
be processed as soon as possible to guarantee good quality of the viral RNA in 
plasma. If the processing procedures cannot take place immediately, the blood 
samples should be stored with extra cares (see Note 4).  
2. Centrifuged the blood samples at 1,600g for 10 min at 4℃. 
3. Transfer serum into new tubes. 
4. Store the serum at -80℃ until RNA extraction (see Note 5). 
 
3.3. RNA Extraction 
The RNA extraction should be performed in a clean and separated area to minimize 
cross contamination.   
1. Add 1.12 mL of AVL buffer to 0.28 mL of serum, mix and incubate at room 
temperature for 10 min. 
2. Add 1.12 mL of absolute ethanol to the mixture and mix. 
3. Apply the mixture to an RNeasy Mini column and wash the column according 
to the manufacturer’s recommendations. 
4. To elute RNA, add 50 µL of AVE buffer onto the silica-gel membrane and 
incubate for 1 min at room temperature. Centrifuge the RNeasy column for 1 
min at 6,000g.  
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5. Stored the extracted RNA at -80℃ until use. 
 
3.4. Real-Time Quantitative RT-PCR 
Serum SARS-CoV RNA is quantified by using one-step real-time quantitative 
RT-PCR (24). In this method, the rTth (Thermus thermophilus) DNA polymerase 
functioned both as a reverse transcriptase and a DNA polymerase (25) (see Note 7). 
Instead of using a two-step RT-PCR approach, one-step RT-PCR, incorporating both 
the reverse transcription and PCR steps in a single tube, should be used to reduce both 
hands-on time and the risk of contamination. In this protocol, the quantifications of 
SARS-CoV RNA are described as follows: 
  
3.4.1. Quantification of pol and N genes of SARS-CoV genome 
1. Prepare calibration curves by serially diluting the synthetic DNA 
oligonucleotides specifying the amplicons with concentrations ranging from 1.0 
x 107 copies to 5 copies (see Note 3). 
2. Set up the RT-PCR reaction mixture for pol and N genes according to Table 1. 
3. Add 11.25 µL of sample RNA, synthetic DNA oligonucleotides (for calibration 
curve) or RNase-free water (for negative blanks) into the reaction mixture. 
4. Perform the real-time RT-PCR reactions in the ABI Prism 7700 Sequence 
Detector with cycling conditions shows in Table 2. 
3.4.2. Data Analysis 
 Amplification data were analyzed and stored by the Sequence Detection System 
Software (Version 1.9; Applied Biosystems). The SARS-CoV RNA concentration is 
expressed as copies per milliliter of serum (copies/mL). The calculation is shown as 
follows: 
 
in which C represents the SARS-CoV RNA concentration in serum (copies/mL), Q 
represents the target quantity (copies/µL) determined by a sequence detector in a PCR, 
VRNA represents the total volume of RNA obtained after extraction (typically 50 µL), 
VSerum represents the volume of serum extracted (typically 0.28 mL). 
The validations of the two real-time RT-PCR systems are described in previous 
publications (13). 
  
C  =  Q  x   
Vserum
 
VRNA 
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5. Notes 
1. Primers and probes are designed with the use of Primer Express® Software v2.0 
(Applied Biosystems). Certain precautions for the design are listed as follows:  
i. The amplicon length should be less than 100 bp, ideally no longer 
than 80 bp. Short amplicon length is preferable due to several 
reasons: (i) The synthetic oligonucleotides specifying the amplicon 
used as a calibration curve is commercially available with size only 
up to 100 bp. Thus, the amplicon length is limited to 100 bp. (ii) 
Amplification with shorter amplicon length are more efficient than 
that of longer amplicon length (18). 
ii. To avoid false positive results arising from co-amplification of genes 
with high homology, it is necessary to perform a BLASTN search 
with the primer and probe sequences against the NCBI GenBank. 
The result of such search will provide information regarding the 
specificivity of the amplification. 
2. Generally, in vitro-transcribed RNA is used as a calibration curve for an absolute 
RNA quantification. This in vitro-transcribed RNA is usually generated by 
subcloning the amplicon behind a T7 RNA polymerase promoter in a plasmid 
vector. However, this procedure is labor intensive and time consuming, which is 
unsuitable when a large number of RT-PCR systems need to be constructed in a 
short period of time. An alternative method is increasingly used to construct a 
calibration curve with the use of synthetic single-stranded oligonucleotides 
specifying the amplification amplicons. Previous data have shown that such single 
stranded oligonucleotides reliably mimic the products of the reverse transcription 
step and produce calibration curves that are identical to those obtained using 
T7-transcribed RNA (18). Due to commercial availability of the synthetic 
oligonucleotides with size only up to 100 bp, the amplicon length should be less 
than 100 bp. 
3. Our studies have revealed that 0.28 mL of plasma is the minimal sample volume 
for the viral RNA detection in plasma. Thus, 3 mL of blood samples should be 
sufficient for testing. 
4. When the blood samples are left unprocessed, their corresponding plasma RNA 
concentrations will fluctuate over time (26). This artifactual fluctuation may due 
to several factors, such as release of RNA from necrotic and/or apoptotic blood 
cells, and the stability of the original and the newly released RNA. To guarantee a 
reliable plasma/serum RNA concentration, we recommend all blood samples, 
including EDTA blood and clotted blood, store at 4℃ and process within 1 hours. 
5. According to our pre-analytical studies, no significant differences in viral RNA 
concentrations were observed between serum stored at -20℃  and -80℃ 
(unpublished data). However, serum samples stored at -80℃ is preferred.  
6. The use of one-step one-enzyme RT-PCR with rTth polymerase has several 
advantages over the two-enzyme RT-PCR: (i) It has been reported that Tth 
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polymerase is more resistant to inhibitors present in biological specimens than Taq 
polymerase (27). (ii) The rTth polymerase is thermostable and thus allows the 
reverse transcription to perform at high temperature (60℃). This minimized the 
secondary structures present in the RNA. (iii) As both reverse transcription and 
PCR carry out in a single tube, this reduces both hands-on time and the risk of 
contamination. 
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Table 1 
Composition of RT-PCR Mix for amplification of pol and N genes of SARS-CoV 
Component Volume for one reaction (µL) Final Concentration 
5X TaqMan EZ Buffer 5 1X 
Mn(OAc)2 (25 mM) 3 3 mM 
dATP (10 mM) 0.75 300 µM 
dCTP (10 mM) 0.75 300 µM 
dGTP (10 mM) 0.75 300 µM 
dUTP (20 mM) 0.75 600 µM 
Forward Primer (10 µM) 0.5 300 nM 
Forward Primer (10 µM) 0.5 300 nM 
Probe (5 µM) 0.5 100 nM 
rTth DNA Polymerase 
(2.5 U/µL) 1 0.1 U/µL 
AmpErase UNG (1 U/µL) 0.25 0.01 U/µL 
Total volume 13.75   
 
 
Table 2 
Cycling Profile for amplification of pol and N genes of SARS-CoV 
Step Temperature Time 
UNG Treatment 50 ℃ 2 min 
Reverse Transcription 60 ℃ 30 min 
Deactivation of UNG 95 ℃ 5 min 
Denaturation 94 ℃ 20 sec 
40 Cycles 
Annealing / Extension 56 ℃ 1 min 
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Figure 1. The locations of the PCR amplicons within the genomic organization of 
SARS Coronavirus. The black bars represent the two PCR amplicons located within 
the genomic structure of SARS coronavirus. The size of the open reading frames 
(ORFs) is drawn to scale, except for orf1ab. The size of the genome is 29.3 kb. 
Shaded boxes represent ORFs encoding the viral polymerase while the filled box (N) 
represents the nucleocapsid region. S represents spike protein; E represents envelope 
protein; M represents membrane protein. 
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Figure 2. Detection of SARS-CoV RNA by real-time quantitative RT-PCR for the 
nucleocapsid region of the viral genome. An amplification plot of Rn, which is the 
fluorescence intensity over the background (Y-axis) against the PCR cycle number 
(X-axis). Each plot corresponds to a particular input synthetic DNA oligonucleotide 
target quantity marked by a corresponding symbol.    
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Figure 3. Serum SARS-CoV RNA levels in SARS patients on the day of hospital 
admission. Box plot of SARS-CoV RNA levels (common logarithmic scale) in sera of 
SARS patients requiring and not requiring ICU admission. Real-time quantitative 
RT-PCR assays towards the nucleocapsid region of the SARS-CoV genome was used 
for quantification. The horizontal lines denote the medians. The lines inside the boxes 
denote the medians. The boxes mark the interval between the 25th and 75th percentiles. 
The whiskers denote the interval between the 10th and 90th percentiles. The filled 
circles mark the data points outside the 10th and 90th percentiles. 
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Figure 4. Serial analysis of plasma SARS-CoV RNA levels in paediatric SARS 
patients. Plots of plasma SARS-CoV RNA levels (Y-axis) against time after the onset 
of fever (day 1 refers the day of fever onset) (X-axis). The duration of fever and the 
periods of steroid and ribavirin treatment are indicated for each case. The arrows in 
patient 1 indicate the time of intravenous methylprednisolone treatment. 
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